KR102585006B1 - Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 - Google Patents

Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 Download PDF

Info

Publication number
KR102585006B1
KR102585006B1 KR1020197017346A KR20197017346A KR102585006B1 KR 102585006 B1 KR102585006 B1 KR 102585006B1 KR 1020197017346 A KR1020197017346 A KR 1020197017346A KR 20197017346 A KR20197017346 A KR 20197017346A KR 102585006 B1 KR102585006 B1 KR 102585006B1
Authority
KR
South Korea
Prior art keywords
delete delete
cancer
egfr
exon
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197017346A
Other languages
English (en)
Korean (ko)
Other versions
KR20190085980A (ko
Inventor
재클린 로비쇼
모니크 닐슨
존 브이. 헤이마치
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102585006(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority to KR1020237033201A priority Critical patent/KR102771603B1/ko
Publication of KR20190085980A publication Critical patent/KR20190085980A/ko
Application granted granted Critical
Publication of KR102585006B1 publication Critical patent/KR102585006B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
KR1020197017346A 2016-11-17 2017-11-17 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 Active KR102585006B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237033201A KR102771603B1 (ko) 2016-11-17 2017-11-17 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662423732P 2016-11-17 2016-11-17
US62/423,732 2016-11-17
US201662427692P 2016-11-29 2016-11-29
US62/427,692 2016-11-29
US201762572716P 2017-10-16 2017-10-16
US62/572,716 2017-10-16
PCT/US2017/062326 WO2018094225A1 (en) 2016-11-17 2017-11-17 Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033201A Division KR102771603B1 (ko) 2016-11-17 2017-11-17 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물

Publications (2)

Publication Number Publication Date
KR20190085980A KR20190085980A (ko) 2019-07-19
KR102585006B1 true KR102585006B1 (ko) 2023-10-05

Family

ID=62146809

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197017346A Active KR102585006B1 (ko) 2016-11-17 2017-11-17 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
KR1020237033201A Active KR102771603B1 (ko) 2016-11-17 2017-11-17 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237033201A Active KR102771603B1 (ko) 2016-11-17 2017-11-17 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물

Country Status (18)

Country Link
US (2) US11446302B2 (enExample)
EP (1) EP3541832A4 (enExample)
JP (2) JP7265985B2 (enExample)
KR (2) KR102585006B1 (enExample)
CN (2) CN117599061A (enExample)
AU (2) AU2017363199B2 (enExample)
BR (1) BR112019010020A2 (enExample)
CA (1) CA3044432A1 (enExample)
CL (1) CL2019001353A1 (enExample)
CO (1) CO2019006218A2 (enExample)
CU (1) CU20190051A7 (enExample)
EC (1) ECSP19043254A (enExample)
MA (1) MA46852A (enExample)
MX (1) MX2019005834A (enExample)
PE (1) PE20191303A1 (enExample)
PH (1) PH12019501116A1 (enExample)
TW (1) TWI782931B (enExample)
WO (1) WO2018094225A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111527103A (zh) * 2017-09-08 2020-08-11 科罗拉多大学董事会,法人团体 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
CA3094108A1 (en) * 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas Systems Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
CA3101657A1 (en) * 2018-06-25 2020-01-02 Spectrum Pharmaceuticals, Inc. Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
SG11202012067YA (en) * 2018-06-25 2021-01-28 Spectrum Pharmaceuticals Inc Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
BR112021004527A2 (pt) * 2018-09-14 2021-06-08 Spectrum Pharmaceuticals, Inc. kits e métodos para tratamento contra câncer
CN113056272A (zh) * 2018-09-21 2021-06-29 光谱医药公司 新的喹唑啉egfr抑制剂
CN113271948B (zh) * 2018-12-21 2024-08-16 得克萨斯大学体系董事会 治疗癌症的联合疗法
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
PH12021552110A1 (en) * 2019-03-29 2022-06-06 Univ Texas Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
AU2020254499A1 (en) * 2019-03-29 2021-10-28 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 insertions
CN113784718A (zh) * 2019-04-17 2021-12-10 得克萨斯大学体系董事会 对携带酪氨酸激酶抑制剂抗性egfr突变的癌细胞具有抗肿瘤活性的化合物
SG11202111120VA (en) * 2019-04-17 2021-11-29 Univ Texas Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
PH12021552798A1 (en) 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US20220296598A1 (en) * 2019-08-23 2022-09-22 Spectrum Pharmaceuticals, Inc. Poziotinib Combination with VEGFR2 Inhibitors and Methods of Use Thereof
US20230069749A1 (en) * 2020-01-29 2023-03-02 Board Of Regents, The University Of Texas System Use of poziotinib for the treatment of cancers with nrg1 fusions
CN115427456A (zh) * 2020-01-29 2022-12-02 得克萨斯州大学系统董事会 基于喹唑啉的酪氨酸激酶抑制剂在具有nrg1融合的癌症的治疗中的用途
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
CN111658650B (zh) * 2020-05-28 2022-05-06 南通大学 Mln4924在制备脉络膜新生血管治疗药物中的应用
UY39342A (es) * 2020-07-27 2022-02-25 Spectrum Pharmaceuticals Inc Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas
US12528869B2 (en) 2020-08-25 2026-01-20 Janssen Biotech, Inc. Treatment of non-small cell lung cancer with EGFR mutations
CA3196712A1 (en) 2020-09-23 2022-03-31 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022072632A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072634A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
JP2024505056A (ja) * 2021-01-29 2024-02-02 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ポジオチニブを用いてがんを処置する方法
JP2024509920A (ja) 2021-03-09 2024-03-05 ヤンセン バイオテツク，インコーポレーテツド Ｅｇｆｒ活性化変異を欠くがんの治療
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023015149A1 (en) * 2021-08-02 2023-02-09 Spectrum Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with poziotinib
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
JP2026508945A (ja) 2023-03-13 2026-03-13 ヤンセン バイオテツク，インコーポレーテツド 二重特異性抗ＥＧＦＲ／ｃ－Ｍｅｔ抗体と抗ＰＤ－１抗体との併用療法
CN121712773A (zh) 2023-06-08 2026-03-20 安塔列斯疗法股份有限公司 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗
WO2025101809A1 (en) * 2023-11-08 2025-05-15 Fate Therapeutics, Inc. Ipsc-derived t cells for solid tumor treatment
CN117587111A (zh) * 2023-11-30 2024-02-23 苏州拓维生物技术有限公司 一种快速批量筛选化合物在激酶细胞系中活性的方法
WO2026038160A1 (en) 2024-08-13 2026-02-19 Janssen Biotech, Inc. Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
CA3278557A1 (en) 2024-08-13 2026-03-01 Janssen Biotech, Inc. Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies
WO2026086737A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Uses and methods of bispecific antibody-drug conjugates for treating tumor diseases
WO2026086740A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use and method of bispecific antibody-drug conjugates for treating tumor diseases

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA190628A (en) 1918-12-05 1919-05-27 William J. Newton Toggle socket
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えｃｔｌａ４ポリペプチドおよびその製造方法
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5869245A (en) 1996-06-05 1999-02-09 Fox Chase Cancer Center Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7935500B2 (en) 2002-03-26 2011-05-03 Massachusetts Institute Of Technology Identifying calcineurin activators for treatment of schizophrenia
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
KR20070108889A (ko) 2005-02-04 2007-11-13 베링거 인겔하임 인터내셔날 게엠베하 만성 비부비동염 치료용 티로신 키나제 억제제의 용도
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
BRPI0717586A2 (pt) * 2006-09-18 2013-10-29 Boehringer Ingelheim Int Método para tratar câncer apresentando mutações do egfr
CN101516376A (zh) * 2006-09-18 2009-08-26 贝林格尔.英格海姆国际有限公司 用于治疗携带egfr突变的癌症的方法
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PL3053932T3 (pl) 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
EP2929350A4 (en) 2012-12-04 2016-11-16 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
RU2016107426A (ru) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
BR112016003247B1 (pt) * 2013-08-22 2022-05-10 Taiho Pharmaceutical Co., Ltd Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kye Young Lee, Molecular diagnosis in lung cancer, J. Lung. Cancer, 2010, 9(1), 9-14. (2010.12.31.)

Also Published As

Publication number Publication date
US20200316071A1 (en) 2020-10-08
AU2023266384A1 (en) 2023-12-07
MX2019005834A (es) 2019-10-14
CO2019006218A2 (es) 2020-01-17
JP7685550B2 (ja) 2025-05-29
CL2019001353A1 (es) 2019-11-08
PH12019501116A1 (en) 2019-11-25
KR20190085980A (ko) 2019-07-19
CN117599061A (zh) 2024-02-27
TWI782931B (zh) 2022-11-11
CU20190051A7 (es) 2020-01-03
KR102771603B1 (ko) 2025-02-24
WO2018094225A1 (en) 2018-05-24
EP3541832A4 (en) 2020-09-30
CN110291104A (zh) 2019-09-27
ECSP19043254A (es) 2019-09-30
US11446302B2 (en) 2022-09-20
KR20230145496A (ko) 2023-10-17
US20230233563A1 (en) 2023-07-27
MA46852A (fr) 2019-09-25
JP2020502059A (ja) 2020-01-23
AU2017363199B2 (en) 2023-08-17
EP3541832A1 (en) 2019-09-25
TW201825098A (zh) 2018-07-16
CN110291104B (zh) 2023-11-03
AU2017363199A1 (en) 2019-07-04
BR112019010020A2 (pt) 2019-08-20
PE20191303A1 (es) 2019-09-23
JP2023100682A (ja) 2023-07-19
JP7265985B2 (ja) 2023-04-27
CA3044432A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
JP7685550B2 (ja) Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物
JP7650814B2 (ja) Ｅｇｆｒまたはｈｅｒ２エクソン２０挿入を有するがん細胞に対する抗腫瘍活性を有する化合物
JP7709384B2 (ja) チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがんに対する化合物
JP2025069282A (ja) Ｅｇｆｒ活性化変異を有するがんを治療するための方法
JP2022529016A (ja) チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがん細胞に対する抗腫瘍活性を有する化合物
JP7700043B2 (ja) Ｈｅｒ２エクソン２１挿入を有するがん細胞に対する抗腫瘍活性を有する化合物
JP7564806B2 (ja) がんの処置のための併用療法
JP7386174B2 (ja) Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物
HK40064724A (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
HK40066138A (zh) 对携带egfr或her2外显子20插入的癌细胞具有抗肿瘤活性的化合物
HK40013571B (zh) 具有针对携带egfr或her2外显子20突变之癌细胞的抗肿瘤活性的化合物
HK40037136A (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
EA041212B1 (ru) Соединения с противоопухолевой активностью в отношении раковых клеток, несущих мутации в 20 экзоне egfr или her2
HK40013571A (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190617

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201116

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221031

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230317

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221031

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230317

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230131

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201116

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20230627

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230621

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230317

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230131

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201116

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230926

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230927

End annual number: 3

Start annual number: 1

PG1601 Publication of registration